--- title: API Synthesis & Manufacturing CDMOs in China path: /services/api-synthesis/china companies_count: 13 --- # API Synthesis & Manufacturing CDMOs in China 13 published CDMOs match API Synthesis & Manufacturing in China. Locations in this set include China, United States, Switzerland, France, Italy, and Japan. Capabilities that show up most often in this set: Small Molecule, Peptide, Antibody-Drug Conjugate (ADC), Biologics (Other), and Biologics (Monoclonal Antibodies). ## Matching companies - [Carbogen Amcis](/companies/carbogen-amcis) - Full-service CDMO offering integrated drug substance and sterile drug product development and manufacturing from early phase through commercialization, with specialized capabilities in API synthesis, process development, analytical services, and stability testing across multiple scales. - [Catalent](/companies/catalent) - Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply. - [Dipharma](/companies/dipharma) - Global CDMO and API manufacturer with 600 employees, 4 cGMP plants, and 75+ years of experience in hazardous chemical synthesis, offering exclusive synthesis services and catalogue APIs with FDA, AIFA, and PMDA inspections since 1970. - [Flamma](/companies/flammagroup) - Privately held small molecule CDMO with FDA-inspected cGMP facilities in Italy, USA, and China, offering custom manufacturing, development, and specialized technologies including HPAPI, continuous flow, and cryogenic API synthesis from early-stage to commercial scale. - [JYMed Peptide](/companies/jymedtech) - Peptide CDMO offering custom synthesis from milligrams to metric tons, with 13 cGMP lines and FDA-, NMPA- and EDQM-approved sites. Provides peptide API manufacturing plus syringe, cartridge and lyophilized finished-dose filling at its Shenzhen site. - [PHT International, Inc.](/companies/phtinternational) - PHT International is a Contract Research, Development, and Manufacturing Organization (CRDMO) offering small-molecule process R&D, cGMP manufacturing from milligrams to multi-tons, and chemical sourcing with global facilities across North America, Europe, and Asia. - [PharmaBlock](/companies/pharmablock) - Leading provider of innovative chemistry products and services for pharmaceutical R&D and commercial manufacturing, with expertise in process development, GMP manufacturing, and low-carbon chemistry solutions. - [Pharmaron](/companies/pharmaron) - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK. - [Piramal Pharma Solutions](/companies/piramalpharmasolutions) - CDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management. - [Porton](/companies/portonpharma) - Porton is a global CDMO offering integrated manufacturing and development services across small molecules, peptides, oligonucleotides, biologics, and conjugates with specialized capabilities in flow chemistry, biocatalysis, and advanced therapies. - [Roquette Pharma Solutions](/companies/roquette) - Roquette is a leading global provider of plant-based ingredients, excipients, and solutions for the pharmaceutical and healthcare industries. - [Yongtai Technology](/companies/yongtaitech) - Yongtai Technology is a chemical manufacturing and contract services provider based in Linhai, Zhejiang, operating pharmaceutical, agrochemical, and materials business divisions with capabilities in API synthesis and chemical manufacturing. - [重庆兴泰濠制药有限公司 (Sintaho)](/companies/sintaho) - China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.